Cipla Rises on Strong Q1 and U.S. Hopes

  Published 11 months ago

Cipla's profit beat estimates on strong India sales; U.S. launches expected to drive future growth amid mixed analyst views.

  • Cipla shares have gained 5% since results; 14 brokerages raised price targets, median now at Rs 1,723.5.
  • HSBC sees FY26 dip in gRevlimid sales but expects U.S. drug launches to cushion impact.
  • Goldman cautious on growth, Jefferies sees H2FY27 U.S. launches as key for future momentum.

You might like these

Borana Weaves IPO & Listing Performance

Wipro Q2 FY26 Revenue, Bookings, Outlook

AI-Driven Public Health Push in India

India's Economic Resilience & Growth Outlook

Trump Backs Nippon Steel's U.S. Steel Bid

R Systems Leads Everest 2025 Engineering

Markets Cool After Rally

News that matters the most ⚡